Compare iShares China Large-Cap ETF (FXI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Summit Therapeutics Inc — how do they compare? iShares China Large-Cap ETF trades at $34.25 (market cap $3.86B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 3.6× iShares China Large-Cap ETF's market cap, and iShares China Large-Cap ETF is more actively traded (16,323,837 versus 6,173,057). Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 150 Days and Summit Therapeutics Inc for 16 Days on average.
| FXI | SMMT | |
|---|---|---|
Market Cap | $3.86B | $13.71B |
Volume | 16,323,837 | 6,173,057 |
52-Week High | $41.08 | $26.38 |
52-Week Low | $31.59 | $12.43 |
Typical Hold Time | 150 Days | 16 Days |
Sector | — | Health |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $33.45 with minimal daily movement (+0.09%), reflecting cautious sentiment amid mixed technical signals. The ETF shows bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. Recent news highlights China's economic challenges including industrial overcapacity and trade tensions, while corporate profits showed strong growth in Q2 2026. The ETF trades at a significant discount to U.S. equities with a P/E ratio approximately half that of the S&P 500.
FXI offers value exposure to Chinese large-caps but faces headwinds from geopolitical risks and economic rebalancing. The Trump-Xi summit provided limited progress on trade tensions, while China's export controls and domestic stimulus measures create uncertainty. Institutional sentiment remains divided between the valuation opportunity and persistent political risks.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
